Business Context and Reporting Period
This Form 8-K Current Report was filed by Black Diamond Therapeutics, Inc. on June 27, 2023. The filing discloses initial clinical data from the dose escalation portion of the Phase 1 clinical study for the investigational drug BDTX-1535, a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Key Financial Metrics
This filing is a current report regarding clinical trial progress and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Data
The report details significant clinical milestones for BDTX-1535 as of the data cutoff date of May 20, 2023:
- Patient Population: A total of 51 patients were treated across seven dose levels (15mg to 400mg once-daily). This included 24 patients with recurrent EGFR+ non-small cell lung cancer (NSCLC) and 27 patients with recurrent glioblastoma multiforme (GBM).
- Pharmacokinetics: The drug demonstrated a linear increase in exposure with an average half-life of approximately 15 hours. Sufficient and sustained steady-state target mutation coverage was achieved at the 100 mg once-daily dose level and above.
- Safety Profile: BDTX-1535 was generally well tolerated. No dose-limiting toxicity was observed at doses of 15-200 mg. At higher doses (300 mg and 400 mg), dose-limiting toxicities such as diarrhea, rash, and stomatitis were observed in some patients.
- Efficacy in NSCLC: In a subgroup of 12 NSCLC patients with measurable disease, 5 demonstrated radiographic confirmed partial response (PR). One additional patient showed an unconfirmed PR, and six had stable disease. Responses were observed across various EGFR mutation types, including acquired C797S resistance mutations.
Guidance, Outlook, and Risks
Future Plans: Based on the data, the Company plans to commence enrollment in two expansion cohorts of NSCLC patients at the 200 mg once-daily dose. These cohorts will target patients with acquired resistance or intrinsic driver mutations who have received up to two prior lines of therapy. The objective is to determine the objective response rate and durability of response to support a potential accelerated approval path with the FDA. An expansion cohort for newly diagnosed NSCLC patients is also planned pending FDA discussion.
Upcoming Updates: The Company intends to provide a clinical update on BDTX-1535 Phase 1 dose escalation data in recurrent GBM patients in the fourth quarter of 2023.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks associated with drug development, regulatory approval, and clinical trial outcomes.
Investor Verification Checklist
- Verify the specific mutation profiles of the 5 NSCLC patients who achieved confirmed partial response to understand the breadth of efficacy.
- Monitor the timeline for the FDA meeting regarding the selection of the recommended Phase 2 dose and expansion cohort design.
- Review the upcoming fourth-quarter 2023 update for GBM data to assess the drug's potential in central nervous system indications.
- Check subsequent filings for the Company's cash runway and capital requirements, as this 8-K does not disclose financial liquidity.